Kemia, Inc. Announces Initiation Of Phase I Trials For Oral Anti-Inflammatory
10/19/2005 5:13:19 PM
SAN DIEGO--(BUSINESS WIRE)--Oct. 6, 2005--Kemia announced today that the company has initiated Phase I clinical trials with KC706, an oral anti-inflammatory. "We are particularly proud that this new drug candidate was conceived within Kemia and has reached the clinic in a relatively short period of time," said Lew Shuster, Kemia's CEO. "Advancing this program to the clinic is an important milestone for the company and a validation of our team's drug discovery and development abilities."
comments powered by